Qiming Venture Partners and Duane Kuang Named to Jazzyear 2025 China Tech Industry Investment Rankings
The list aims to recognize investors and investment firms with outstanding performance and strong growth momentum in 2025, who have exerted profound influence on the development of China's tech industry.
Recently, Jazzyear released its 2025 China Tech Industry Investment Rankings, an annual list recognizing investors and investment firms with standout performance, strong growth momentum, and deep influence on China's tech industry. The rankings comprehensively showcase how leading institutions have excelled amid trends dominated by hard tech and ecosystem-driven strategies.
Qiming Venture Partners was named one of the Top 3 Best Tech VC Firms in China for 2025, while Duane Kuang, Founding Managing Partner of Qiming Venture Partners, was honored among the Top 30 Best Tech Investors of 2025.
Qiming Venture Partners
Named
Top 3 Best Tech VC Firms in China 2025
Duane Kuang, Founding Managing Partner of Qiming Venture Partners
Named
Top 30 Best Tech Investors 2025
Selection Criteria
The Jazzyear 2025 China Tech Industry Investment Rankings evaluated funds based on AUM, fundraising capability, investment capacity, track record, and external reputation, with additional verification analysis to enhance accuracy.
Jazzyear noted that in 2025, global capital markets have shown strong recovery and deep integration, with investment firms actively deploying capital and funds flowing markedly toward technology innovation, pushing tech industry financing to new heights. Against this backdrop, China's tech industry has officially entered a critical phase of "consolidation and convergence."
The investment landscape in 2025 is characterized by "hard tech dominance, long-termism, and ecosystem-oriented strategies." Investors are no longer chasing short-term concept hype, but instead making sustained bets on technological moats, commercialization capabilities, and ecosystem synergy — focusing on core technologies such as AI computing infrastructure (GPUs, intelligent computing centers), embodied AI components (high-precision sensors, motion controllers), quantum computing, and biochips, with the patience to nurture companies over a decade.
Source | Jazzyear
Past Coverage
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Genrix Bio (688520.SH), Arbutus Biopharma, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.